Aion Therapeutic Inc (AION) AI Stock Analysis

• Market Cap: C$4.84M
• Dividend Yield: N/A
• Average Volume (3M): 49.40K
• Price to Earnings (P/E): ―
• Beta (1Y): -2.72
• Revenue Growth: N/A
• EPS Growth: -69.79%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 62
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 483,549,260
• 10 Day Avg. Volume: 62,820
• 30 Day Avg. Volume: 49,396
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 5.92
• Price to Cash Flow (P/CF): -2.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Aion Therapeutic Inc's overall stock score is low due to significant financial difficulties, including negative equity and ongoing operational inefficiencies. The technical analysis indicates a bearish trend, and the negative P/E ratio alongside the lack of dividend yield further detract from its investment appeal.

Aion Therapeutic Inc Business Overview & Revenue Model

Company Description

Aion Therapeutic Inc (AION) is a biotechnology company focused on the development and commercialization of therapies and products derived from natural sources, including medicinal mushrooms, cannabis, and other plant-based compounds. The company operates within the healthcare and pharmaceutical sectors, leveraging cutting-edge research to produce innovative treatments aimed at addressing a range of health conditions.

How the Company Makes Money

Aion Therapeutic Inc makes money through the development and sale of its proprietary therapeutic products and formulations. The company's revenue streams include direct product sales to consumers and healthcare providers, as well as potential licensing agreements with other pharmaceutical companies. Key partnerships with research institutions and technology platforms also play a role in its ability to innovate and expand its product offerings, thereby contributing to its revenue. Additionally, Aion may engage in joint ventures or strategic alliances to enhance its market presence and drive sales growth.

Aion Therapeutic Inc Financial Statement Overview

Summary

Aion Therapeutic Inc is facing significant financial difficulties across all major financial statements. The company needs to address both operational inefficiencies and financial leverage to stabilize its financial health. Immediate strategic changes are required to improve profitability and cash flow sustainability.

Income Statement

The company has shown some revenue growth recently, but profitability metrics like gross profit margin, net profit margin, and EBIT margin are negative, indicating significant financial challenges. The negative EBITDA margin further reflects ongoing operational inefficiencies and substantial losses.

Balance Sheet

Aion Therapeutic Inc has a negative stockholders' equity, indicating financial distress. The high debt-to-equity ratio suggests excessive leverage, while the negative equity ratio highlights the precarious financial position. The company's return on equity is also negative due to consistent net losses.

Cash Flow

The cash flow metrics are concerning, with negative free cash flow growth and poor operating cash flow to net income ratio, reflecting ongoing cash burn and inadequate cash generation. This necessitates careful management to prevent liquidity issues.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
1.15M	367.48K	0.00	0.00	0.00	0.00
	Gross Profit
173.76K	163.12K	-17.30K	-65.29K	―	-111.05K
	EBIT
-1.07M	-1.19M	-1.08M	―	―	-996.64K
	EBITDA
-6.41M	-6.07M	-89.52K	-3.68M	-7.95M	-240.59K
	Net Income Common Stockholders
-6.73M	-6.29M	-256.66K	-3.82M	-8.27M	-672.83K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
93.69K	68.34K	336.00	239.83K	239.83K	612.79K
	Total Assets
1.54M	702.86K	210.67K	150.14K	1.60M	3.34M
	Total Debt
2.40M	2.08M	826.47K	744.06K	566.53K	958.91K
	Net Debt
2.31M	2.01M	826.13K	504.23K	326.70K	346.12K
	Total Liabilities
5.65M	4.57M	2.94M	2.56M	1.21M	1.20M
	Stockholders Equity
-4.11M	-3.87M	-2.73M	-2.41M	397.46K	2.13M
Cash Flow		Free Cash Flow
-1.26M	-845.04K	-41.40K	-2.79M	-3.58M	-756.38K
	Operating Cash Flow
-1.26M	-845.04K	-41.40K	-1.35M	-2.13M	-551.75K
	Investing Cash Flow
-23.36K	-289.42K	135.19K	-1.38M	-1.38M	-333.19K
	Financing Cash Flow
1.22M	1.12M	163.25K	1.20M	3.00M	-125.00K

Aion Therapeutic Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AION, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.67 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AION.

Aion Therapeutic Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEO	68 Neutral	C$360.07M	―	-3.15%	4.54%	-15.41%	-69.47%
CURA	51 Neutral	$1.00B	―	-23.33%	―	0.67%	19.14%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
CYBN	42 Neutral	$1.97M	―	-58.79%	―	―	51.37%
AION	33 Underperform	C$4.84M	―		―	―	-69.79%